First patients receive experimental cancer drug in early safety trial
NCT ID NCT06493864
Summary
This is the first human study of an experimental drug called BL-B16D1 for patients with advanced breast cancer or other solid tumors that have spread or cannot be surgically removed. The trial aims to find the safest dose and understand how the drug behaves in the body. It will enroll 21 adults whose cancer has continued to grow despite standard treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, China
Contact
Contact
Contact
Conditions
Explore the condition pages connected to this study.